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Abstract
The use of race in biomedical research has, for decades, been a source of social controversy.
However, recent events, such as the adoption of racially targeted pharmaceuticals, have raised
the profile of the race issue. In addition, we are entering an era in which genomic research is
increasingly focused on the nature and extent of human genetic variation, often examined by
population, which leads to heightened potential for misunderstandings or misuse of terms
concerning genetic variation and race. Here, we draw together the perspectives of participants in
a recent interdisciplinary workshop on ancestry and health in medicine in order to explore the
use of race in research issue from the vantage point of a variety of disciplines. We review the nature
of the race controversy in the context of biomedical research and highlight several challenges to
policy action, including restrictions resulting from commercial or regulatory considerations, the
difficulty in presenting precise terminology in the media, and drifting or ambiguous definitions of
key terms.
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Recent advances in biomedical research promise increasing
insights into complex contributions to traits and diseases,
and there is hope that these will lead to global health
benefits [1,2]. Analytical and social-justice considerations
both recommend thoughtful assessment of the role of social
identity, particularly racial or ethnic identity, in the design,
conduct and dissemination of clinical and basic science
research. Controversies ranging from James Watson’s
comments on racial differences in intelligence [3] to the
adoption of racially targeted pharmaceuticals, such as the
African-American heart-failure drug BiDil [4-7], remind us
that use of the concept of race in biomedical research can
have far-reaching, often unanticipated social consequences.
The problem of race in scientific research is not a new one,
and the issue seems to perpetually reappear and remain
fundamentally unresolved [8]. We are, however, entering a
new era in which the fruits of initiatives, such as the Human
Genome Project [9,10], the International Haplotype Map
Project [11], and the recently proposed 1000 Genomes
Project [12], promise to elaborate more fully than ever
before the nature and extent of human genetic variation and
its relation to social identity. A recent interdisciplinary
workshop, ‘Ancestry in health and medicine; expanding the
debate’, hosted by the Alberta Health Law Institute and the
McLaughlin-Rotman Centre for Global Health, in Toronto,
Canada, sought to debate the current status and concerns
surrounding these new scientific data, how we relate genetic
variation to individual and population-level differences in
observable traits, and what this might mean for the effective
addressing of significant disparities in health status and
disease. A central motivating consideration was how best to
secure the anticipated benefits of genetic and related forms
of biomedical research in the face of inevitable misunder-
standings or misuse concerning genetic variation and race.
Here, we draw together the perspectives of the scholars who
participated in the workshop, who have considered the race
issue from the vantage point of a variety of disciplines:
anthropology, bioethics, clinical medicine, ethical, social,
cultural studies, genetic epidemiology, genome sciences,
global heath research, law and the social sciences. We review
the nature of the race controversy in the context of biomedical
research and highlight several challenges to policy action.
The race dilemma in research
At the heart of ongoing debates about the value and use of
racial categories in biomedical research are disagreements
about the underlying rationale (and motivation) for strati-
fying study cohorts and what to do with resulting obser-
vations. Although there is considerable interest in using
social or political categories in the descriptive assessment of
health outcome similarities and differences, several scholars
have suggested that the subsequent attribution of causality
to those categories is unjustified and potentially harmful
[13,14]. So, although there is much agreement that race (and
other forms of social identification) matters to health, there
is little agreement about why or how race matters, how best
to study its effects and how to translate and communicate
research results from racially stratified studies (see Box 1).
Persistent disagreements about how best to understand race
as an object of scientific inquiry complicate matters further.
Racial definitions can fluctuate according to social context,
geographic location, historical period and personal experience.
Indeed, it is not uncommon for the same individual to report
their racial identity differently in different contexts and at
different points in their lives [15-17]. For these and related
reasons many scholars view racial identity as primarily a
social construct [18-22], and one that can misdirect the
categorization of participants in biomedical research. Others
see racial identity as correlated with a mix of social and
biological risk factors that should be recognized and
disentangled, even used to advantage, in an effort to explain
and address health disparities [23-26].
Despite research correlating population genetic identity with
geographic proximity [27-30], many researchers hold that
self-identified racial or ethnic identity is a poor proxy for
underlying genetic relatedness [31-34]. As a consequence,
scientists with an interest in identifying genetic-association
studies with disease are turning to DNA-based estimates of
‘ancestry’ as a basis for stratifying study samples and
controlling for background genetic differences unrelated to
disease risk [35-37]. Geneticists have also begun to use
ancestry informative markers (AIMs) to identify groups and
individuals subject to recent genetic admixture and use this
information in methods such as admixture mapping
[38-40]. In both gene-association and admixture studies,
assessing ancestry is seen as preferable because it
circumvents the problems of self-reporting, although major
axes of differentiation continue to be drawn along conti-
nental lines, recapitulating previously used racial distinc-
tions: African, European, Native American, and so on.
Although ancestry estimation has the potential to control
biases due to genetic confounding, in isolation its use defers,
rather than addresses, the important problem of how social
and biological risk factors interact in the context of health -
including the production of racial health disparities. Research
that simultaneously assesses both genetic and environmental
contributions to disease risk, drug response and other health-
related variation, and that deliberately puts such findings in
the context of self-identified race, is urgently needed [13,41-
43]. In the absence of such additional evidence, and despite
its amorphous nature, the multi-dimensional and contested
concept of race will probably continue to have an important
place in biomedical research for many years to come.
The continuing salience of race as a research variable places
researchers in the unenviable position of having to negotiate
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complicated, and often controversial, terrain. Given the
potential for misinterpretation and misapplication of
research findings, great care must be used in the characteri-
zation of study samples and the interpretation of obser-
vations (Box 2). Available research tells us that such rigor is
often absent in the reporting of race and ethnicity in the
biomedical literature [44-50]. In addition, researchers must
remain aware of the manner in which their work could be
translated, both clinically and in the popular press (Box 2).
Challenges to change
How can we move forward? Many journals, research entities
and academic commentators have provided relevant recom-
mendations (Box 2). Yet concerns persist, and race and related
concepts continue to be used in an inconsistent and potentially
misleading manner within biomedical research [44,48-50].
The concept of race has a long and complex social history
[51], and the research community operates within the con-
straints imposed by this history and its associated social
structures. This overriding reality is one of the primary
reasons why the use of race remains a controversial and
uneasy concept in research. However, there are other challen-
ges that make progress difficult, despite the numerous policy
recommendations. Understanding these tendencies, trends
and social forces may help us to more effectively use existing
recommendations and address social concerns. What follows,
although not comprehensive, is a list of some of the most
salient challenges that emerged from the workshop.
Commercial and regulatory imperatives
Decisions on whether or how to use race in biomedical
research and clinical practice do not take place in isolation.
Often they are shaped by commercial and regulatory impera-
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Box 1. Examples of concerns with the use of ‘race’ in genetic research
Examples of research concerns
Stratification by race is being used on the assumption it can serve as a proxy for genetic similarity, but there is
disagreement regarding the degree to which race correlates with genetic variation [23,27-33,70,71].
There is a lack of agreement both in the public sphere and among researchers on what is meant by the term ‘race’. In
genetic research it is not being defined or applied consistently, nor is a rationale for the analysis of race in studies being
consistently provided. This leads to a lack of clarity about the groups being investigated, hindering reproducibility and
generalizability between studies and slowing scientific progress [65,72-76].
Examples of social concerns
Stratification by race in genetic research can over-emphasize the role of genetics as the basis for health disparities,
deflecting research funding and attention away from the substantial socio-economic and political determinants of
inequities [74,77-80].
The use of race to categorize groups in genetic research can lead to over-emphasis of the relative magnitude of genetic
differences between populations and to the ‘reification’ of race as a natural genetically determined system of human
classification (leading to ‘racialization’ and a belief in genetic underpinnings for social inequities and differences
between groups) [54,66,79,81-83].
The use of racial or population groups in studies to identify the genetic variation underlying disease susceptibilities can
lead to ‘racialization’ of disease, whereby the disease state becomes irrevocably identified and linked with that group.
This can lead to several secondary outcomes, including the discrimination and stigmatization of members of the group
in question, and decreased access to information, surveillance and treatment that could be valuable to other groups
[65,77,84,85].
Example of clinical/healthcare concerns
The descriptive use of race in genetic and biomedical research can lead to racial stereotyping in clinical practice. For
example, the use of perceived or self-identified race as a proxy for genotype in prescribing most often overly simplifies
the concept of pharmacogenomics. Diagnosis or assessment of disease risk on the basis of race can similarly result in
serious medical errors [13,86-89].
tives that reward or require the use of racial categories in
particular ways that may not serve constructive purposes.
Much biomedical data, for example, is produced as a result
of regulatory mandates that direct the collection of data
using social categories of race derived from such sources as
national census tables [13,46,52,53]. Such ‘racialized’ data
necessarily raise questions of how best to manage the
relationship between social census categories of race and the
biomedical data being produced by researchers and clini-
cians. Moreover, once introduced into the biomedical arena,
race can take on a life of its own, leading to the retrospective
framing of data and/or the prospective design of product
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Box 2. Existing recommendations for the use and reporting of race and ethnicity in biomedical
research
Study design
1. Endeavor to measure relevant social, economic, environmental, biological or genetic factors directly rather than
using race or ethnicity as proxies [90].
2. Use race/ethnicity (and gender and socio-economic status) only when data relevant to the underlying social
mechanisms have been collected and included in the analysis. Attempt to measure as many alternative variables as
possible. These may include, but should not be limited to: racism and discrimination, socio-economic status, social
class, personal or family wealth, environmental exposures, insurance status, age, diet and nutrition, health beliefs
and practices, education level, language spoken, religion, tribal affiliation and country of birth [90-93].
3. Use terms that are as descriptive as possible, rather than catch-all terms in common use, and use terms that reflect
how groups were demarcated [90,94].
4. When populations are compared, use groupings that are precisely defined and of similar resolution [65].
5. When possible, use terminology and naming for groups that are acceptable to the groups themselves [90,95-98].
6. Ensure that assignment of subjects to research categories is appropriate to the research question being asked [90].
Study reporting
1. Define the variables being used [65,91,93,99,100].
2. Justify the relevance of the variables used to the research hypothesis [65,90-94,99-105].
3. Explain precisely how the data were collected, such as whether the data were self-reported or assigned by others or,
if it was by survey, what terms were included in the forms or other materials [65,90,91,99,101,102].
4. Describe and justify the categories used to group populations [93].
5. Consider conferring with the community from which participants were drawn to verify that results are presented in a
manner acceptable to them [95-98].
6. Consider carefully the implied relationship between study populations and the populations to which findings are
generalized [65].
7. Consider carefully the social and ethical implications of the study results [62].
8. Prepare a lay summary of the study conclusions, taking care to use accurate terminology, for use in communicating
to the popular press [62].
9. Be prepared to follow up and set the record straight if study results are misinterpreted [62].
development in ‘racialized’ terms that were not originally
contemplated by the researchers [54-56]. It also seems likely
that market forces will push toward terminology that
captures a larger population and has more immediate public
recognition [57]. Narrowly defined terms, such as ancestry,
are likely to have less public recognition than race.
Media representations
The popular press is an important source of health
information, particularly for the general public [58]. Although
the relationship between media representations and public
perceptions of biomedical research is complex [59], there is
some evidence that the media can influence social
perceptions and attitudes, even about race [60]. There are
certainly examples of news reports that include a thorough
examination of the challenges associated with using race in
biomedical research [61], but media representations often
simplify the science and use concepts such as race without
explaining how the social category relates to the research
outcome [62]. Given the limited space and time available to
write most science stories, this is hardly surprising. The
research community, in an effort to translate the research
results to the lay public, can also use terminology that does
not accurately reflect or represent the research conducted
(Box 2). For example, a study might have used ancestry as a
variable but, in its media report, racial descriptors are used
to describe the significance of the findings in the popular
press [63].
Definition drift and slippage
In response to the social concerns associated with the notion
of race, new terminology has been suggested - the hope
being that this new terminology will be both more
scientifically precise and have less historical and social
baggage. For example, the term ethnicity emerged as an
alternative to race [64]. However, there is often a migration
back to the origin term or the new term simply comes to be
understood to mean the same thing as the old one [65].
Given that the social category of race has the most cultural
resonance, this slippage is likely to be from the more specific
terminology toward the broader, and perhaps more
inaccurate, notion of race [26,62].
Definition ambiguity
The final challenge is the need to strategically tolerate the
ambiguity of racial identity. Because, as described above, the
relevance of race and of race categories far exceeds the arena
of scientific discourse and becomes the concern of govern-
ment regulation, media accounts and language debate,
science cannot independently dictate its meaning or invent
new terms to replace it. Moreover, the features that make
race socially useful - its fluidity, ambiguity and contingency -
and that feed its social ubiquity and thus contribute to its
scientific utility also work against tidy definitions. These
features of race cannot be reasoned away. Nor, however, can
they be used as an excuse to ignore standard scientific
requirements for explaining research terms and justifying
design choices. Instead, they need to be recognized and self-
consciously engaged, as part of an iterative process directed
at clarifying the import of human genetic variation in the
long term and of using genetic insights to help eliminate,
rather than reinforce, disparities in health status.
Mitigation strategy
Race is best understood as the result of a process informed
by social values and institutional practices that imbue
superficial differences between groups, such as skin color,
eye shape or language, with unwarranted significance.
Historically, this has been informed by hierarchical thinking,
in which group differences and social inequalities are
naturalized and rearticulated as biological realities [66].
Genomic research that uses racial categories in the investi-
gation of genetic contributions to disease can also in-
advertently support such ‘racialization’ and influence how
findings of group differences are interpreted and, in turn,
translated into clinical care and health policy.
Clearly, although the recognition that certain susceptibility
variants are more prevalent in certain groups can have
health benefits, such observations should not validate the
politically and historically charged concept of race or
support assumptions that the entire range of attributes
ascribed to race have a biological basis. There is a need to
develop strategies to mitigate the inappropriate and
potentially inaccurate use of categorizing terminology. The
available recommendations, outlined in Box 2, have merit.
But there are numerous social forces and tendencies, such as
those outlined above, that challenge progress towards
constructive change.
Future policy and social-science work should focus on
exploring the influence of these social forces. For example,
although some research in this area has already been done
[62,67], a more nuanced understanding of how data on
human genomic variation are interpreted by media, and in
turn assimilated by the public, is needed. Recommendations
for communication strategy could be used to raise the aware-
ness of researchers as to how their work is apprehended by
lay audiences (Box 2), especially journalists. Engagement
and education of both scientists and media on their social
and ethical responsibilities would be a related actionable
strategy (Box 2). In the arena of clinical trials and genetic
epidemiological research, the social impact and scientific
utility of alternative methods of subject identification and
reporting of findings could be explored. Most importantly,
consideration should be given not only to ensuring that
relevant policy recommendations are effectively imple-
mented, but that they are being followed.
Finally, it must be recognized that the discussion and
analysis surrounding the use of race, ethnicity or ancestry in
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medicine is, for the most part, flowing from scholars in
North America and Europe. However, a number of countries,
including Mexico, India [68,69], Thailand and South Africa,
are already doing, or planning to undertake, projects
studying human genetic diversity within their own popula-
tions; and in many others, such as Brazil, extensive
admixture has created a continuum of ancestral proportions
among individuals that challenge racial classification. It will
therefore be important that experts from communities in
both the emerging economies and developing countries also
contribute to this very important debate.
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